-
1 Comment
AID Life Science Holdings Limited is currently in a long term uptrend where the price is trading 6.3% above its 200 day moving average.
From a valuation standpoint, the stock is 79.8% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 3.0.
AID Life Science Holdings Limited's total revenue sank by 76.1% to $800K since the same quarter in the previous year.
Its net income has increased by 44.7% to $-34M since the same quarter in the previous year.
Finally, its free cash flow grew by 63.3% to $-14M since the same quarter in the previous year.
Based on the above factors, AID Life Science Holdings Limited gets an overall score of 4/5.
| Sector | Financial Services |
|---|---|
| Exchange | HK |
| Industry | Asset Management |
| CurrencyCode | HKD |
| ISIN | KYG2955N1034 |
| Beta | 0.46 |
|---|---|
| Target Price | None |
| Dividend Yield | 0.0% |
| PE Ratio | None |
| Market Cap | 33M |
AID Life Science Holdings Limited is a publicly owned investment manager. Through its subsidiaries, it provides asset management services in Hong Kong and internationally. The company offers investment advisory and corporate services, as well as provides fund administration and management, asset management, and wealth management services. It also holds available-for-sale investments. The company was formerly known as Healthoo International Technology Holdings Limited. AID Life Science Holdings Limited was founded in 1998 and is based in Central, Hong Kong.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 8088.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
